LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3001 | 4935 | 0.6082 | 0.5418 |
MDA-MB-231 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 2447 | 4935 | 0.4960 | 0.3856 |
MDA-MB-231 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 1907 | 4935 | 0.3864 | 0.2160 |
MDA-MB-231 | PI103 | 10 | uM | LJP6 | 72 | hr | 1311 | 1382 | 4935 | 0.2802 | 0.0278 |
MDA-MB-231 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4858 | 5079 | 0.9562 | 0.9544 |
MDA-MB-231 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4826 | 5079 | 0.9501 | 0.9482 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 3488 | 5079 | 0.6868 | 0.6500 |
MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3204 | 5079 | 0.6308 | 0.5792 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 2456 | 5079 | 0.4836 | 0.3786 |
MDA-MB-231 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1311 | 2027 | 5079 | 0.3991 | 0.2496 |
MDA-MB-231 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4763 | 5079 | 0.9380 | 0.9354 |
MDA-MB-231 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4722 | 5079 | 0.9298 | 0.9269 |
MDA-MB-231 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4632 | 5079 | 0.9120 | 0.9077 |
MDA-MB-231 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4664 | 5079 | 0.9185 | 0.9147 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4949 | 5079 | 0.9745 | 0.9737 |
MDA-MB-231 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 1311 | 4646 | 5079 | 0.9148 | 0.9107 |
MDA-MB-231 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 2350 | 4935 | 0.4764 | 0.3565 |
MDA-MB-231 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 813 | 4935 | 0.1648 | -0.2214 |
MDA-MB-231 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 723 | 4935 | 0.1467 | -0.2674 |
MDA-MB-231 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 763 | 4935 | 0.1547 | -0.2469 |
MDA-MB-231 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 804 | 4935 | 0.1630 | -0.2258 |
MDA-MB-231 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 1311 | 818 | 4935 | 0.1658 | -0.2191 |
MDA-MB-231 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4376 | 4935 | 0.8868 | 0.8782 |
MDA-MB-231 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4369 | 4935 | 0.8852 | 0.8764 |
MDA-MB-231 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3658 | 4935 | 0.7410 | 0.7094 |